



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville MD 20857

August 23, 2006

FILE COPY


Cynthia Pearson
National Women's Health Network
514 Tenth Street NW
Suite 400
Washington, District of Columbia 20004

Dear Ms Pearson:

Your petition requesting the Food and Drug Administration to stop Solvay Pharmaceuticals and Breckenridge Pharmaceuticals from marketing estrogens & methyltestosterone combination products for vasomotor symptoms associated with menopause, was received by this office on 08/22/2006. It was assigned docket number 2006P-0346/CP 1 and it was filed on 08/22/2006. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,


Gloria Ortega, Deputy Director
Division of Dockets Management
Office of Management Programs
Office of Management

2006P- 0346

ACK 1